Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olverembatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 17/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olverembatinib SCHEMBL3424528 | 1.00 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29514988 | 1.00 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953130 | 0.99 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456095 | 0.99 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29515011 | 0.99 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29652687 | 0.97 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953403 | 0.97 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29464044 | 0.97 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456239 | 0.96 | ABL1 (0.92) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL22699129 | 0.95 | ABL1 (0.90) | ABL1FGFR1CYP2C9PDGFRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| EP-4701664-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | JOINT BIOSCIENCES SH LTD (CN) | 2026-01-22 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| WO-2025201518-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. (CN) | 2025-10-02 | — | — | WO | claimed |
| US-20250149116-A1 | ABL1 FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | claimed |
| WO-2025059046-A1 | SOS1 INHIBITORS FOR USE IN THE TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE BLOOD CANCERS | KUMQUAT BIOSCIENCES INC. (US) | 2025-03-20 | — | — | WO | claimed |
| CN-116806149-A | Methods and compositions for treating pathological conditions involving neovascularization using IDO 1-dependent angiogenic cells | 兰肯瑙医学研究所 | 2023-09-26 | — | — | CN | claimed |
| WO-2023150718-A2 | OLVEREMBATINIB INHIBITS CYTOKINE UPREGULATION ASSOCIATED WITH CYTOKINE RELEASE SYNDROME | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023114759-A2 | ABL INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023081927-A2 | TREATING CHEMORESISTANT FORMS OF LEUKEMIA AND OTHER CANCERS THAT OVEREXPRESS RNA BINDING PROTEIN FXR1 | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | claimed |
| CN-114533879-A | Combination therapy for the treatment of cancer | 广州顺健生物医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022105836-A1 | COMBINATION THERAPIES FOR TREATING CANCER | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. (CN) | 2022-05-27 | — | — | WO | claimed |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | ABL1 555/4885FGFR1 194/4885CYP2C9 4813/4885 |
| US-20250144224-A1 | ABL INHIBITORS AND USES THEREOF | ABL1, ABL2, ALK | ABL1 1/4885FGFR1 306/4885CYP2C9 4113/4885 |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | ABL1 555/4885FGFR1 194/4885CYP2C9 4813/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | ABL1 43/4885FGFR1 245/4885CYP2C9 4046/4885 |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | ERBB2, BTK, ERBB3 | ABL1 23/4885FGFR1 73/4885CYP2C9 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.